AREV Life Sciences Global Corp.
AREVF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -80.7% | 33.8% | -2.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.3% | 72.6% | 100% | 66.3% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $2 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $1 | $2 | $1 | $3 |
| Operating Income | -$1 | -$1 | -$0 | -$3 |
| % Margin | -2,827.7% | -587% | -237.3% | -1,554.4% |
| Other Income/Exp. Net | -$0 | $1 | -$1 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$3 |
| % Margin | -2,940.4% | -388.4% | -550.4% | -1,640% |
| EPS | -0.048 | -0.036 | -0.068 | -0.36 |
| % Growth | -33% | 47.1% | 81% | – |
| EPS Diluted | -0.048 | -0.05 | -0.068 | -0.36 |
| Weighted Avg Shares Out | 30 | 27 | 15 | 9 |
| Weighted Avg Shares Out Dil | 30 | 27 | 15 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$3 |
| % Margin | -2,668.7% | -312.8% | -262.3% | -1,568.7% |